Oral dnaJP1 is a 14 amino acid sequence delivered once daily to rheumatoid arthritis (RA patients). Oral dnaJP1 has completed a 160 patient double-blind, placebo controlled Phase II clinical trial in RA patients which was funded by a $5 million grant from the National Institute of Health.
Nicholas Stergis, Adeona’s CEO, said: “This notice of allowance provides further intellectual property protection for various analog molecules which are related to dnaJP1, our oral, once-daily therapy for the treatment of RA which has already completed a double-blind, placebo-controlled, Phase II clinical trial.
“Upon issuance, we will add this patent to our growing set of intellectual property which encompasses over 47 issued, pending US and international patents related to this novel technology.”